Lanean...

FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro

Although regorafenib has demonstrated survival benefits in patients with metastatic colorectal and gastrointestinal stromal tumors, no proven biomarker has been identified for predicting sensitivity to regorafenib. Here, we investigated preclinical activity of regorafenib in gastric and colorectal c...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Oncol
Egile Nagusiak: Cha, Yongjun, Kim, Hwang‐Phill, Lim, Yoojoo, Han, Sae‐Won, Song, Sang‐Hyun, Kim, Tae‐You
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6026866/
https://ncbi.nlm.nih.gov/pubmed/29573334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12194
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!